Organic Synthesis at the Service of Biology and Medicine

为生物学和医学服务的有机合成

• 批准号: 10704547
• 负责人: Ouathek Ouerfelli
• 金额: $ 23.3万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-17 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10704547
• 关键词: Binding; Biology; Cancer Detection; Chemicals; Chemistry; Collaborations; Communities; Core Facility; Detection; Development; Disease; FDA approved; Funding; Head; Human Resources; Knowledge; Leadership; Malignant Neoplasms; Medicine; Memorial Sloan-Kettering Cancer Center; NCI Center for Cancer Research; Organic Synthesis; Pharmaceutical Chemistry; Pharmaceutical Preparations; Prevention; Research; Research Personnel; Services; Specialist; Therapeutic Agents; cancer biomarkers; chemical synthesis; collaborative environment; preclinical study; stem; success; synergism; tool

Dr. Ouathek Ouerfelli directs the organic synthesis core facility (OSCF) at Memorial Sloan Kettering Cancer Center (MSK) since 2004. He is committed to provide chemistry services for the MSK research community and the development of new tools and therapeutic agents for cancer detection, prevention, and treatment. The core head possesses more than 25 years of chemistry collaborations and service of MSK investigators, more than half of whom are NCI grantees. Along these lines, he contributed to major endeavors by eminent colleagues who are NCI grantees such as Dr. Charles Sawyers (R01 CA155169) which led to an FDA approved drug, Dr. Scott Lowe (R01 CA155169) with several projects that are showing promise, as well as Dr. Craig Thompson (RO1 CA168802) for the development of a new cancer markers among others. He maintains a state-of-the art facility with expert professional personnel in chemical synthesis. OSCF has now the capability to support medicinal chemistry efforts to evolve agents in support of MSK investigators. Under his leadership, the core has greatly facilitated preclinical studies at the Center.

Ouathek Ouerfelli博士指导纪念斯隆的有机合成核心设施（OSCF） 凯特林癌症中心（MSK）自2004年以来。他致力于提供化学服务， MSK研究社区和新工具和治疗剂的开发， 癌症检测、预防和治疗。核心头拥有超过25年的 化学合作和MSK研究人员的服务，其中一半以上是NCI 受赠人。沿着这些路线，他为杰出的同事们的重大努力做出了贡献， NCI的受资助者，如Charles Sawyers博士（R01 CA155169），导致FDA批准的药物， 博士斯科特洛（R01 CA155169）与几个项目，是显示承诺，以及博士。 克雷格汤普森（RO1 CA168802）为开发一种新的癌症标志物等。 他拥有最先进的设施，拥有化学合成方面的专业人员。 OSCF现在有能力支持药物化学工作，以发展药物， MSK的调查员。在他的领导下，核心大大促进了临床前研究， 中心。

项目成果

Mechanistic details of the actinobacterial lyase-catalyzed degradation reaction of 2-hydroxyisobutyryl-CoA.

放线菌裂解酶催化 2-羟基异丁酰-CoA 降解反应的机制细节。

• DOI: 10.1016/j.jbc.2021.101522
• 发表时间: 2022-01
• 期刊: The Journal of biological chemistry
• 作者: Zahn M;König G;Pham HVC;Seroka B;Lazny R;Yang G;Ouerfelli O;Lotowski Z;Rohwerder T
• 通讯作者: Rohwerder T